Corneal Versus Conjunctival Delivery Using a Delivery Device - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

September 1, 2005

Last Updated Date

March 1, 2007

Start Date ^†

Current Primary Outcome Measures ^†

IOP level in the study eye

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00143429 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Original Secondary Outcome Measures ^†

Change in ocular safety assessments.
Ocular and systemic adverse events throughout the study period

Descriptive Information

Brief Title ^†

Corneal Versus Conjunctival Delivery Using a Delivery Device

Official Title ^†

Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device

Brief Summary

Compare the antihypertensive efficacy of three methods for installing Xalatan

Detailed Description

Study Phase

Phase II

Study Type ^†

Interventional

Study Design ^†

Treatment, Randomized, Single Blind, Active Control, Crossover Assignment, Safety/Efficacy Study

Condition ^†

Glaucoma, Open-Angle
Ocular Hypertension

Intervention ^†

Drug: Xalatan

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Withdrawn

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

History of closed/barely open anterior chamber angle or a history of angle closure

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00143429

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Pfizer

Collaborators ^††

Investigators ^†

Study Director:

Pfizer CT.gov Call Center

Pfizer

Information Provided By

Pfizer

Verification Date

October 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.